What insurance policy changes affect code L98.0?

There are 7 tracked policy changes affecting code L98.0, including updates from Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code L98.0?

Payers that have issued tracked updates for code L98.0 include: Aetna, Independence Blue Cross.

How do I get notified when code L98.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code L98.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code L98.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

L98.0 Insurance Policy Changes

ICD-10 L98.0 is officially defined as "Pyogenic granuloma." code L98.0 is referenced in 7 tracked payer policy changes from Aetna and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code L98.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 14, 2026High impact
Benign Skin Lesion Removal (CPB 0633, reviewed 2025-09-25)
This is historical material: Aetna's Clinical Policy Bulletin 0633 on benign skin lesion removal, last reviewed 2025-09-25 and first detected by PolicyChanges on 2026-08-14. Aetna covers removal of common benign lesions (such as moles, skin tags, sebaceous cysts, seborrheic keratoses and dermatofibromas) only when a listed medical reason is documented, such as a biopsy showing dysplasia or malignancy, recurrent irritation, symptoms, inflammation, infection or a lesion that blocks vision, and treats removal without those reasons as cosmetic. No effective date is stated, so confirm this is the current version before relying on it.
Independence Blue Cross · Effective Apr 1, 2026Medium impact
MA11.071b, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)
Independence Blue Cross reissued MA11.071b on 04/01/2026 to reaffirm its coverage position on selective photothermolysis using pulsed-dye lasers (PDL). The policy clarifies that PDL treatment for psoriasis, molluscum contagiosum, basal cell carcinoma, cutaneous lupus erythematosus, and cutaneous sarcoidosis remains experimental/investigational and non-covered. The policy also updated criteria for rosacea treatment to align with current clinical standards and added specific ICD-10 diagnosis codes for non-covered indications.
Independence Blue Cross · Effective Apr 1, 2026Medium impact
11.08.04i, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)
Independence Blue Cross reissued Policy 11.08.04i on 04/01/2026 reaffirming its continuing position on PDL treatment coverage. The policy clarifies medically necessary indications (port wine stains, hemangiomas, hypertrophic/keloidal scars, pyogenic granulomas, viral warts, and rosacea), designates specific conditions as experimental/investigational (psoriasis, molluscum contagiosum, basal cell carcinoma, cutaneous lupus), and updates rosacea treatment criteria to require 6-month failed medical management before PDL coverage. Billing teams must verify patient diagnoses against the expanded ICD-10 code list and confirm medical necessity documentation for rosacea cases.
Aetna · Identified Oct 1, 2026Medium impact
Benign Skin Lesion Removal (CPB 0633, reviewed 2026-09-09)
Aetna's Clinical Policy Bulletin 0633 covers removal of benign skin lesions such as moles, skin tags, sebaceous cysts and seborrheic keratoses when a listed clinical reason applies, such as suspicion of malignancy, recurrent irritation, symptoms, inflammation, or infection. When none of those reasons applies, Aetna treats the removal as cosmetic, and it treats ionized plasma jet therapy and pre-surgical skin ultrasound as experimental. The source is dated by its review on 2026-09-09 and states no effective date for a change, so the billing team should confirm the current bulletin before billing these removals.
Aetna · Identified Oct 1, 2026Medium impact
Pulsed Dye Laser Treatment (CPB 0559, reviewed 2026-09-18)
Aetna's Clinical Policy Bulletin 0559 covers pulsed dye laser treatment. It considers the pulsed dye laser medically necessary for conditions including actinic keratoses that have not adequately responded to imiquimod, 5-FU or cryosurgery, infantile hemangiomas, port wine stains and hemangiomas on the face and neck, and verrucae after at least two conventional therapies have failed. It considers the laser experimental, investigational or unproven for other indications such as active acne, onychomycosis and non-melanoma skin cancer, and cosmetic for conditions such as rosacea, solar lentigines and striae distensae.
Aetna · Identified Aug 14, 2026Medium impact
Double Balloon Enteroscopy (CPB 0737, reviewed 2025-11-13)
Aetna considers double balloon enteroscopy medically necessary for dilation of small bowel strictures in Crohn's disease, evaluating suspected small bowel malignancies, evaluating the colon after incomplete colonoscopy, suspected Meckel's diverticulum with an indefinite imaging work-up, obscure GI bleeding with objective evidence of recurrent bleeding, removing entrapped foreign bodies in the small bowel, removing large polyps greater than 10 mm in Peutz-Jeghers syndrome, GI bleeding when the small intestine is the source, and use with ERCP in individuals with surgically altered upper GI anatomy. Aetna considers double balloon enteroscopy experimental, investigational or unproven for other indications, including detection of small bowel neuroendocrine tumors, small bowel varices, treatment of intussusception, treatment of angioectasia (type 1 small bowel vascular lesions), and treatment of post-operative bile leakage after hepaticojejunostomy. Combined double balloon enteroscopy and endoscopic ultrasound for evaluation of Crohn's disease is also considered experimental, investigational or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Pulsed Dye Laser Treatment (CPB 0559, reviewed 2025-08-22)
Pulsed dye laser treatment is medically necessary for actinic keratoses that failed to adequately respond to imiquimod, 5-FU, or cryosurgery, for capillary malformation with overgrowth or vascular malformation, for genital warts when home therapy with podophyllotoxin or imiquimod has failed, for granuloma faciale, for infantile hemangiomas, and for port wine stains and other hemangiomas on the face and neck. It is also medically necessary for keloids or hypertrophic scars from an injury or surgical procedure that cause significant pain requiring chronic analgesic medication or significant functional impairment, for multiple superficially located glomangiomas in the face and neck where surgical excision is not practical, for pyogenic granuloma in the face and neck, for symptomatic angiolymphoid hyperplasia that has failed medical therapy, and for verrucae after at least two conventional therapies have failed. Pulsed dye laser is considered experimental, investigational, or unproven for other conditions, including active acne, onychomycosis, hidradenitis suppurativa, molluscum contagiosum, and morphea, and cosmetic for conditions including rosacea, facial redness, solar lentigines, and striae distensae.

Watch L98.0

Get one email when a payer policy names L98.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Benign Skin Lesion Removal (CPB 0633, reviewed 2025-09-25)

MA11.071b, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)

11.08.04i, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)

Benign Skin Lesion Removal (CPB 0633, reviewed 2026-09-09)

Pulsed Dye Laser Treatment (CPB 0559, reviewed 2026-09-18)

Double Balloon Enteroscopy (CPB 0737, reviewed 2025-11-13)

Pulsed Dye Laser Treatment (CPB 0559, reviewed 2025-08-22)

What insurance policy changes affect code L98.0?

Which payers have updated policy for code L98.0?

How do I get notified when code L98.0 policy changes?

Why do payers change policies for code L98.0?